Core Insights - Gelteq Limited announced positive preclinical results indicating its proprietary gel formulation achieved significantly higher bioavailability compared to a leading antihistamine product [1][2] - The formulation demonstrated a 38–45% increase in systemic exposure and absorption, along with higher peak concentrations while maintaining a comparable time to peak plasma concentration [2][3] - The results validate Gelteq's platform for enhancing the performance of established drugs and open opportunities for a broader portfolio of pharmaceutical applications [3][4] Company Overview - Gelteq is a clinical and science-based company based in Melbourne, Australia, focused on developing gel-based oral delivery solutions for various applications including prescription drugs and nutraceuticals [5] - The proprietary formulation technology aims to address challenges in conventional drug delivery such as taste masking and swallowing difficulties [5] Strategic Implications - The positive results support the company's strategy to partner and develop gel-based formulations across a wide range of therapeutically relevant compounds, potentially expanding beyond the antihistamine market [4] - The company plans to pursue FDA approval for an antihistamine product and engage with pharmaceutical partners interested in next-generation drug delivery formats [4]
Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform